title: Outcomes of 1014 naturalistically treated inpatients with major depressive episode.
abstract: Due to strict exclusion criteria the generalizability of randomized controlled trials appears to be limited. Therefore, outcomes of naturalistically treated depressive inpatients with respect to depression mean scores, response and remission rates were evaluated. This was a multicenter trial, conducted in 12 psychiatric hospitals in Germany with a follow-up period of 4years. Patients were assessed biweekly from admission to discharge with diverse psychopathological rating scales. All patients (n=1014) met DSM-IV criteria for major depressive episode. Results are presented only for the acute inpatient treatment period. Mean inpatient treatment duration was 53.6+/-47.5days. Reduction on depression scales was evident as soon as week 2 and remained significant. Mean HAMD-17 total score decreased from 22.3 to 8.8. A total of 68.9% were classified as responders (> or =50% reduction of the initial HAMD-17 score), whereas 51.9% achieved remission (HAMD-17 total score < or =7). Of those who ultimately achieved response more than 40% did so within the first 2weeks. An individualized naturalistic inpatient treatment approach appears to be beneficial in terms of effectiveness.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Germany. florian.seemueller@med.uni-muenchen.de
authors.forename: Florian
authors.initials: F
authors.lastname: Seemüller
authors.forename: Michael
authors.initials: M
authors.lastname: Riedel
authors.forename: Michael
authors.initials: M
authors.lastname: Obermeier
authors.forename: Michael
authors.initials: M
authors.lastname: Bauer
authors.forename: Mazda
authors.initials: M
authors.lastname: Adli
authors.forename: Klaus
authors.initials: K
authors.lastname: Kronmüller
authors.forename: Florian
authors.initials: F
authors.lastname: Holsboer
authors.forename: Peter
authors.initials: P
authors.lastname: Brieger
authors.forename: Gerd
authors.initials: G
authors.lastname: Laux
authors.forename: Wolfram
authors.initials: W
authors.lastname: Bender
authors.forename: Isabella
authors.initials: I
authors.lastname: Heuser
authors.forename: Joachim
authors.initials: J
authors.lastname: Zeiler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Gaebel
authors.forename: Eva
authors.initials: E
authors.lastname: Dichgans
authors.forename: Roland
authors.initials: R
authors.lastname: Bottländer
authors.forename: Richard
authors.initials: R
authors.lastname: Musil
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000628:therapy*; D004565:Electroconvulsive Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010789:Phototherapy; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D012892:Sleep Deprivation; D050781:Transcranial Magnetic Stimulation; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents